NCT01705002 - Intravenously Administered Pegylated Liposomal Mitomycin-C Lipid-based Prodrug (PROMITIL) in Cancer Patients With Solid Tumors. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

November 30, 2017

Study Completion Date

June 30, 2018

Conditions

CancerSolid TumorMetastatic Colorectal Cancer (mCRC)

Interventions

DRUG

Promitil

2 mg/kg dose IV

DRUG

Capecitabine

1000 mg dose BID PO for days 1-21 for Combination Cohort and on day 1-14 on Triple combination Cohort

DRUG

Bevacizumab

for Triple combination cohort an IV dose of 5 mg/kg on day 1 at 4 week interval. For the 3 weekly cohort an IV dose of 7.5 mg/kg at 3 week interval.

Trial Locations (4)

Tel-Aviv Sourasky Medical Center, Tel Aviv

Rambam Health Care Campus, Haifa

Shaare Zedek Medical Center, Jerusalem

Chaim Sheba Medical center, Ramat Gan